News stories about Affymetrix (NASDAQ:AFFX) have been trending somewhat positive this week, according to Accern. The research firm scores the sentiment of press coverage by reviewing more than twenty million news and blog sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Affymetrix earned a media sentiment score of 0.17 on Accern’s scale. Accern also gave news articles about the scientific and technical instruments company an impact score of 45.7300742672002 out of 100, meaning that recent press coverage is somewhat unlikely to have an impact on the stock’s share price in the near future.
TRADEMARK VIOLATION NOTICE: This report was originally reported by The Ledger Gazette and is owned by of The Ledger Gazette. If you are accessing this report on another site, it was stolen and republished in violation of U.S. and international copyright and trademark legislation. The original version of this report can be accessed at https://ledgergazette.com/2017/10/18/affymetrix-affx-getting-somewhat-favorable-media-coverage-analysis-finds.html.
Affymetrix, Inc (Affymetrix) is a provider of life science products and molecular diagnostic products that enable parallel analysis of biological systems at the gene, protein and cell level. The Company operates through two business segments: Affymetrix Core and eBioscience. The Affymetrix Core segment focuses on the development, manufacture and commercialization of systems for genetic analysis in the life sciences, agricultural biotechnology (AgBio) and diagnostic industry.
Receive News & Ratings for Affymetrix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Affymetrix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.